These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22212966)

  • 1. Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study.
    Jacobsen SJ; Jacobson DJ; McGree ME; St Sauver JL; Klee GG; Girman CJ; Lieber MM
    Mayo Clin Proc; 2012 Jan; 87(1):34-40. PubMed ID: 22212966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
    Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
    JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort.
    St Sauver JL; Jacobson DJ; Girman CJ; Lieber MM; McGree ME; Jacobsen SJ
    J Urol; 2006 Mar; 175(3 Pt 1):1018-22; discussion 1022. PubMed ID: 16469608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men.
    Rhodes T; Jacobson DJ; McGree ME; St Sauver JL; Girman CJ; Lieber MM; Klee GG; Demissie K; Jacobsen SJ
    Urology; 2012 Mar; 79(3):655-61. PubMed ID: 22386420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men's Health Study.
    Sarma AV; St Sauver JL; Jacobson DJ; McGree ME; Klee GG; Lieber MM; Girman CJ; Hollingsworth JM; Jacobsen SJ;
    Urology; 2014 Jan; 83(1):88-93. PubMed ID: 24139354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.
    Oesterling JE; Jacobsen SJ; Klee GG; Pettersson K; Piironen T; Abrahamsson PA; Stenman UH; Dowell B; Lövgren T; Lilja H
    J Urol; 1995 Sep; 154(3):1090-5. PubMed ID: 7543605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection.
    Wallner LP; Morgenstern H; McGree ME; Jacobson DJ; St Sauver JL; Jacobsen SJ; Sarma AV
    Cancer Epidemiol Biomarkers Prev; 2011 Mar; 20(3):501-8. PubMed ID: 21242331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
    Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
    J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men.
    Rhodes T; Jacobson DJ; McGree ME; St Sauver JL; Sarma AV; Girman CJ; Lieber MM; Klee GG; Demissie K; Jacobsen SJ
    J Urol; 2012 Jan; 187(1):87-91. PubMed ID: 22093190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of changes in prostate specific antigen in early stage prostate cancer.
    Pearson JD; Carter HB
    J Urol; 1994 Nov; 152(5 Pt 2):1743-8. PubMed ID: 7523722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal evaluation of prostate-specific antigen levels in a case-control study.
    De Biasi F; Londero D; Praturlon S; Di Donna A; Feruglio GA; Guerra UP
    Eur Urol; 1996; 29(2):184-8. PubMed ID: 8647144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effect of digital rectal examination on serum prostate-specific antigen levels. A prospective study.
    Cevik I; Türkeri LN; Ozveri H; Ilker Y; Akdaş A
    Eur Urol; 1996; 29(4):403-6. PubMed ID: 8791045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
    Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; deKernion JB; Walsh PC; Scardino PT; Lange PH; Subong EN; Parson RE; Gasior GH; Loveland KG; Southwick PC
    JAMA; 1998 May; 279(19):1542-7. PubMed ID: 9605898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population.
    Roehrborn CG; Pickens GJ; Carmody T
    Urology; 1996 Jan; 47(1):59-66. PubMed ID: 8560664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.
    Agarwal DK; Costello AJ; Peters J; Sikaris K; Crowe H
    BJU Int; 2000 Apr; 85(6):690-5. PubMed ID: 10759667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.